Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Определение HER2/neu-статуса по гистологическому материалу – есть ли пространство для дискуссии?
Определение HER2/neu-статуса по гистологическому материалу – есть ли пространство для дискуссии?
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье рассмотрены возможность определения HER2-статуса на цитологическом материале, полученном при аспирационной биопсии, а также возможные диагностические ошибки данного метода.
Ключевые слова: HER2-статус, HER2-тестирование, HER2-положительный РМЖ, ИГХ, FISH/CISH
Key words: HER2-status, HER2-testing, HER2-positive BrC, IHC, FISH/CISH
Ключевые слова: HER2-статус, HER2-тестирование, HER2-положительный РМЖ, ИГХ, FISH/CISH
________________________________________________
Key words: HER2-status, HER2-testing, HER2-positive BrC, IHC, FISH/CISH
Полный текст
Список литературы
1. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62: 209–43.
2. Ягудина Р.И., Куликов А.Ю., Нгуен Т. Обзор зарубежных фармакоэкономических исследований применения Герцептина при лечении рака молочной железы. Фармакоэкономика. 2009; 2: 28–35.
3. Ганьшина И.П., Степанова Е.В. Место герцептина в онкологической практике. Русский медицинский журнал. Онкология. 2003; 11: 680–5.
4. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18–43.
5. Vocaturo A, Novelli F, Benevolo M et al. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrepR-Processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era. The Oncologist 2006; 11: 878–86.
6. Bedard YC, Pollet AF, Leung SW et el. Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status. Acta Cytol 2003; 47: 979–84.
7. Sartelet H, Lagonotte E, Lorenzato M et al. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma. J Clin Pathol 2005; 58: 864–71.
8. Nizzoli R, Bozzetti C, Crafa P et al. Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. Diagn Cytopathol 2003; 28: 142–6.
9. Bozzetti C, Nozzili R, Guazzi A et al. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Annals of Oncology 2002; 13: 1398–403.
10. Bozzetti C, Personeni N, Nizzoli R et al. HER-2/neu Amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer (Cancer cytopathology) 2003; 99: 310–5.
11. Moriki T, Takahashi T, Ueta S et al. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Diagnostic Cytopathology 2004; 30: 251–6.
12. Corkill ME, Katz R. Immunocytochemical staining of c-erbB-2 oncogene in fine-needle aspirates of breast carcinoma: a comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol 1994; 11: 250–4.
13. Troncone G, Panico L., Vetrani A et al. c-erbB-2 expression in FNAB and matched surgical specimens of breast cancer. Diagn Cytopathol 1996; 14: 135–9.
14. Solomides CC, Zimmerman R, Bibbo M. Semiquantitative assessment of c-erbB-2 (HER-2) status in cytology specimens and tissue sections from breast carcinoma. Anal Quant Cytol Histol 1999; 21: 121–5.
15. Brifford M, Hecene K, Le Doussal V. Immunohistochemistry on cell blocks from fine needle cytopunctures of primary breast carcinomas and lymph node metastases. Modern Pathology 2000; 8: 841.
16. Nassar A, Cohen C, Siddiqui M. Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3). Diagnostic Cytopathology 2009; 37: 865–70.
17. Tapia C, Savic S, Wagner U et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Research 2007; 3: 31.
18. Волченко Н.Н., Савостикова М.В. Атлас цитологической и иммуноцитохимической диагностики опухолей. М., 2010.
19. Sottnik JL, Guth AM, Mitchell LA et al. Minimally invasive assessment of tumor angiogenesis by fine needle aspiration and flow cytometry. Angiogenesis 2010; 13: 251–8.
20. Fowler JL, Lachar WA. Application of immunohistochemistry to cytology. Arch Pathol LabMed 2008; 132: 373–83.
21. Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. Journal of Clinical Oncology 2004; 22: 3046–52.
2. Ягудина Р.И., Куликов А.Ю., Нгуен Т. Обзор зарубежных фармакоэкономических исследований применения Герцептина при лечении рака молочной железы. Фармакоэкономика. 2009; 2: 28–35.
3. Ганьшина И.П., Степанова Е.В. Место герцептина в онкологической практике. Русский медицинский журнал. Онкология. 2003; 11: 680–5.
4. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18–43.
5. Vocaturo A, Novelli F, Benevolo M et al. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrepR-Processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era. The Oncologist 2006; 11: 878–86.
6. Bedard YC, Pollet AF, Leung SW et el. Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status. Acta Cytol 2003; 47: 979–84.
7. Sartelet H, Lagonotte E, Lorenzato M et al. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma. J Clin Pathol 2005; 58: 864–71.
8. Nizzoli R, Bozzetti C, Crafa P et al. Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. Diagn Cytopathol 2003; 28: 142–6.
9. Bozzetti C, Nozzili R, Guazzi A et al. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Annals of Oncology 2002; 13: 1398–403.
10. Bozzetti C, Personeni N, Nizzoli R et al. HER-2/neu Amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer (Cancer cytopathology) 2003; 99: 310–5.
11. Moriki T, Takahashi T, Ueta S et al. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Diagnostic Cytopathology 2004; 30: 251–6.
12. Corkill ME, Katz R. Immunocytochemical staining of c-erbB-2 oncogene in fine-needle aspirates of breast carcinoma: a comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol 1994; 11: 250–4.
13. Troncone G, Panico L., Vetrani A et al. c-erbB-2 expression in FNAB and matched surgical specimens of breast cancer. Diagn Cytopathol 1996; 14: 135–9.
14. Solomides CC, Zimmerman R, Bibbo M. Semiquantitative assessment of c-erbB-2 (HER-2) status in cytology specimens and tissue sections from breast carcinoma. Anal Quant Cytol Histol 1999; 21: 121–5.
15. Brifford M, Hecene K, Le Doussal V. Immunohistochemistry on cell blocks from fine needle cytopunctures of primary breast carcinomas and lymph node metastases. Modern Pathology 2000; 8: 841.
16. Nassar A, Cohen C, Siddiqui M. Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3). Diagnostic Cytopathology 2009; 37: 865–70.
17. Tapia C, Savic S, Wagner U et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Research 2007; 3: 31.
18. Волченко Н.Н., Савостикова М.В. Атлас цитологической и иммуноцитохимической диагностики опухолей. М., 2010.
19. Sottnik JL, Guth AM, Mitchell LA et al. Minimally invasive assessment of tumor angiogenesis by fine needle aspiration and flow cytometry. Angiogenesis 2010; 13: 251–8.
20. Fowler JL, Lachar WA. Application of immunohistochemistry to cytology. Arch Pathol LabMed 2008; 132: 373–83.
21. Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. Journal of Clinical Oncology 2004; 22: 3046–52.
Авторы
А.М.Борбат1, Е.В.Ткаченко2, К.М.Пожарисский3
1 ПАО ГУЗ ЯО Областная клиническая онкологическая больница, Ярославль;
2 Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический), Санкт-Петербург;
3 Российский научный центр радиологии и хирургических технологий, Санкт-Петербург
1 ПАО ГУЗ ЯО Областная клиническая онкологическая больница, Ярославль;
2 Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический), Санкт-Петербург;
3 Российский научный центр радиологии и хирургических технологий, Санкт-Петербург
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.